TickerTrends Research on Bachem Holding AG (BCHMY)

主要经营地 Switzerland

详细生意模式 Peptide Contract Development & Manufacturing Organization (CDMO) with clinical pipeline segment (CMC Development) converting to recurring commercial revenue. GLP-1 validated peptides accelerate broader peptide therapeutics pipeline growth. CMC Development +29.7% YoY to CHF304M vs Commercial API +5% to CHF343.4M shows transition from single-class to multi-class manufacturing bottleneck.

护城河 🟢 Core infrastructure for structural peptide expansion with manufacturing bottleneck moat; differentiated peptide capabilities; Building K expansion adds 1-ton annual capacity; US $250M 2026-2030 investment

估值水平 EV/EBITDA 23.89x

EV/Market Cap $5.0B / $5.0B

网络观点 Mispriced as GLP-1 play when actually diversified peptide CDMO with CMC pipeline converting to recurring commercial revenue with multi-year lag; forecasts beat H1 2026 consensus

AI观点 Bachem positioned well for peptide expansion but premium valuation (24x EBITDA) already prices in significant growth; Building K ramp and US expansion provide technical credibility but execution risk on capacity utilization remains material